# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹2,270 Cr** (Q2 FY'26) (+4%) · Domestic: **₹1,031 Cr** (+6%) · International: **₹1,238 Cr** (+8%) * **PAT:** **₹251 Cr** (Q2 FY'26) (+24%) * Gross Margin: 60.8% (+20 bps YoY) * EBITDA Margin: 19.3% (+0.1 pp QoQ) * **Net Debt:** **₹837 Cr** (Q2 FY'26) * **Depreciation & Amortization:** **₹105 Cr** · **Interest Cost:** **₹33 Cr** (Q2) ## B. Revenue Growth * **Strong International Momentum:** Revenue growth led by **double-digit international expansion** and resilient domestic performance, with favorable regional mix contributing to top-line resilience. * **Record Profitability:** Highest-ever quarterly PAT reflects operating leverage and sustained margin recovery despite modest revenue growth. ## C. Profit Margins * **Margin Expansion Underway:** Gross margin improved significantly on **favorable product and business mix**, while EBITDA margin rose on productivity gains and operating leverage. * **H2 Improvement Expected:** Operating margin trend remains positive with **20 bps YoY improvement (FX-adjusted)**, and management anticipates acceleration toward full-year margin guidance. ## D. Balance Sheet * **Debt Uptick Due to M&A:** Net debt increase in H1 attributed to **acquisition of residual stake in Zuventus**, a non-recurring item not in prior guidance, altering near-term leverage trajectory. ## E. Cash Flow * **Cash Flow Outlook Strengthening:** With sustained profitability and **depreciation at ₹105 Cr**, future cash generation is poised to support strategic investments and capital allocation. --- # 2. Product & Therapy Performance ## A. Key Figures * Diabetes Portfolio Contribution: 1.5 months in quarter · 8% to 8.5% organic growth ## B. Diabetes Portfolio * **Strategic Ambition in GLP-1:** Emcure targeting early leadership in India’s obesity market, leveraging a **25 crore obese/overweight population** and strategic partnerships. * **Poviztra vs. Mounjaro:** Poviztra (semaglutide) and Mounjaro (tirzepatide) are distinct molecules; management expresses confidence in Poviztra’s growth potential, citing **broader clinical data and additional indications**. * **Post-Acquisition Momentum:** Diabetes portfolio, acquired from Sanofi, is outperforming targets due to active promotion and integration of former Sanofi talent, strengthening diabetology positioning. * **Tenecteplase Adoption:** Gaining strong traction in stroke, with **positive real-world feedback from off-label use** fueling interest in formal registration. ## C. ARV & Lenacapavir * **Lenacapavir Catalyst:** Near-term regulatory submissions expected across multiple countries, positioning ARV segment for future growth. ## D. Chronic & Women’s Health * **Chronic Disease Expansion:** Cardio-diabetes and gynecology portfolios gaining momentum via acquisitions, in-licensing, and launches of **chirality-based products**. * **Semaglutide Treatment Duration:** Expected to last **6 to 8 months**, supporting sustained revenue contribution in chronic care. * **Dual Growth Engine:** Both chronic and women’s health (acute) segments seen as key growth drivers, with Ureaderm exemplifying success in premiumization and **Gen Z appeal through repackaged innovation**. --- # 3. Geography & Market Mix ## A. Key Figures * Domestic Business Growth: 10.6% YoY (vs. industry) · 8.5%–9% organic (ex-Sanofi) * International Segment Growth: >16% YoY · Europe: 22.7% YoY (₹444 Cr, +7%) · Canada: 17.5% YoY (₹348 Cr, +5%) · Emerging Markets: 8.6% YoY (₹446 Cr) * **Non-ARV Segment Growth (RoW):** **Teens** YoY ## B. Domestic Business * **Outperformance with Broad-Based Momentum:** Domestic business grew strongly, outpacing the industry, led by robust expansion in gynecology, cardiology, dermatology, consumer health, and diabetes segments. * **Resilient Organic Growth:** Excluding Sanofi oral anti-diabetes brands, underlying domestic growth remained healthy within the **5%–9%** range, indicating solid core momentum. ## C. Europe Growth * **Europe Surge Driven by Launch Momentum:** Strong 22% growth fueled by Amphotericin B ramp-up and Manx acquisition benefits, with recent launches in Italy and the UK. * **Pan-European Expansion Underway:** Amphotericin B expected to reach all targeted markets by H2, with upcoming entries in France and Germany following completed launches in Italy. ## D. Canada Performance * **Sustained Mid-Teens Growth Trajectory:** Canada delivered 17% growth on market share gains and new product launches, with management signaling continued strength through year-end. ## E. Emerging Markets * **ARV Business Backed by Tender Wins:** Healthy order book with multi-year visibility, supported by success in key tenders including South Africa. * **Non-ARV Outpaces ARV with Regulatory Tailwinds:** RoW sales driven by fast-growing non-ARV portfolio; Tenecteplase currently approved for myocardial infarction, with stroke indication expected to add meaningful upside upon expansion. --- # 4. Partnerships & In-Licensing ## A. Key Figures * **Sanofi Portfolio Revenue:** **₹200 Cr** (~established products) ## B. Novo Nordisk Deal * **Strategic Launch Advantage:** Partnership with Novo Nordisk on **Poviztra (semaglutide)** positions Emcure to capture early market share in India’s obesity market (~25–35 crore addressable) ahead of post-patent competition in Mar '26. * **Global Credibility, Local Reach:** Access to Novo’s global clinical data and real-world evidence from **40 million users** enhances product trust; Emcure will distribute imported supply via its **5,000+ field force** and national network.[D] * **Strategic Pivot Confirmed:** Shift from internal generic Ozempic development to the Novo partnership deemed **more lucrative**, with no Indian manufacturing planned. * **Commercial Flexibility:** Agreement allows Emcure to sell in all regions where Novo operates (no exclusivity carve-outs) and **pursue generic semaglutide internationally** without restriction. ## C. In-Licensing Strategy & Portfolio Dynamics * **Growth Pillar with Margin Discipline:** In-licensing remains a core growth driver alongside R&D; deals evaluated for **portfolio economics and ROCE accretion**, targeting **mid-teens EBITDA margins**. * **Sanofi Portfolio Revival:** Established brand portfolio (~₹200 Cr) expected to grow **in line with industry averages** due to renewed promotion; open to expanded role including manufacturing. * **Strategic Interest in Metabolic Assets:** Emcure would **favorably consider** acquiring Sanofi’s diabetic portfolio if divested, aligning with metabolic therapy expansion goals. ## D. M&A & Consolidation * **Domestic & International Focus:** M&A remains central to growth—targeting **new domestic segments** and **bolt-on deals in key international markets** (e.g., Canada, UK, Europe) to leverage existing infrastructure. * **Zuventus Fully Consolidated:** Minority stake acquisition completed in early October, enabling full control and anticipated **back-end synergies** for the coming quarter. --- # 5. Manufacturing & Supply Chain ## A. Supply Chain Buildup * **Inventory Buildup for Launch Readiness:** Elevated inventory levels reflect strategic stockpiling ahead of new product launches in Europe and Canada, aligned with stronger H2 demand forecasts. * **Near-Term Normalization Expected:** Inventory is projected to return to normal levels over the next six months as launch timelines progress. ## B. In-House Production * **Vertical Integration Supports Global Expansion:** Increased in-house manufacturing strengthens supply chain control and enhances execution capability for international rollouts. * **Sanofi Manufacturing Remains External:** Sanofi currently self-manufactures its portfolio products; any shift to Emcure via CMO is potential but not an active focus. ## C. Market Approvals * **Canada Filing on Track:** Regulatory submission planned before year-end remains on schedule, supporting near-term market entry ambitions. --- # 6. R&D & Pipeline Progress ## A. R&D Strategy & Pipeline Focus * **Headline:** Expanding biosimilar approvals in emerging markets for **tenecteplase** across key indications including myocardial infarction and acute ischemic stroke. * **Headline:** Internal R&D remains the primary engine for portfolio development, with selective in-licensing pursued only when aligned with specialty divisions and field force. ## B. Complex Injectables & Manufacturing * **Headline:** Pipeline emphasis on complex injectables and biosimilars for emerging markets, leveraging in-house manufacturing to support future margin expansion. ## C. Innovation Partnerships * **Headline:** Active discussions with innovator firms on novel molecules signal strategic pipeline diversification and alignment with next-generation treatment trends. --- # 7. Pricing & Regulatory Risks ## A. Tender Pricing Risk * **Stable ARV Pricing:** ARV pricing remains resilient in recent tenders, including South Africa, with no material adverse impact. --- # 8. Guidance & Outlook ## A. Key Figures * **Margin Expansion Guidance:** **150 bps** improvement expected this year (core operations only) * Debt-Free Target: Expected by end of next year (18–24 months post-acquisition) ## B. Organic Growth Target * **Resilient Growth Trajectory:** Double-digit organic growth resumed in Q1 despite prior GST-related headwinds, with sustained outperformance expected at industry rates plus **100–200 bps**. * **Full-Year Guidance Confirmed:** Company remains on track to deliver its original FY targets. ## C. Margin Expansion * **Base Margin Upside:** Strong focus on operational excellence driving **150 bps expansion** this year, supported by product mix shift and chronic portfolio ramp-up. * **Structural Leverage:** Multi-year margin expansion anticipated from **MR productivity gains** and scaling of high-margin domestic chronic brands. * **In-Licensing as ROCE Catalyst:** Strategic deals to boost cash flow and returns, separate from core margin improvement. ## D. Strategic Roadmap * **Three-Pillar Strategy:** Prioritizing **big brand expansion**, leadership in **biologics and formulations R&D**, and targeted **in-licensing** to accelerate domestic growth.